Overall Survival Analysis From KYPROLIS® (carfilzomib) Phase 3 Endeavor Trial Published In The Lancet Oncology Read more about Overall Survival Analysis From KYPROLIS® (carfilzomib) Phase 3 Endeavor Trial Published In The Lancet Oncology
New Economic Analysis Based On Repatha® (Evolocumab) Outcomes Data Published In JAMA Cardiology Read more about New Economic Analysis Based On Repatha® (Evolocumab) Outcomes Data Published In JAMA Cardiology
Amgen To Present New Data From The Repatha® (Evolocumab) Cardiovascular Outcomes Study At ESC Congress 2017 Read more about Amgen To Present New Data From The Repatha® (Evolocumab) Cardiovascular Outcomes Study At ESC Congress 2017
Amgen And Humana Partner For Improved Health Outcomes And Efficiency Read more about Amgen And Humana Partner For Improved Health Outcomes And Efficiency
Repatha® (Evolocumab) Phase 3 Cognitive Function Study Results Published In The New England Journal Of Medicine Read more about Repatha® (Evolocumab) Phase 3 Cognitive Function Study Results Published In The New England Journal Of Medicine
Amgen Submits Supplemental Biologics License Application For Prolia® (denosumab) In Glucocorticoid-Induced Osteoporosis Read more about Amgen Submits Supplemental Biologics License Application For Prolia® (denosumab) In Glucocorticoid-Induced Osteoporosis
Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 980 To US Food And Drug Administration Read more about Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 980 To US Food And Drug Administration
Amgen Announces 2017 Third Quarter Dividend Read more about Amgen Announces 2017 Third Quarter Dividend
FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For Repatha® (evolocumab) To Include Data On Reducing Risk Of Cardiovascular Events Read more about FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For Repatha® (evolocumab) To Include Data On Reducing Risk Of Cardiovascular Events
Amgen Reports Second Quarter 2017 Financial Results Read more about Amgen Reports Second Quarter 2017 Financial Results
